Terbinafine-induced subacute cutaneous lupus erythematosus in two patients with systemic lupus erythematosus successfully treated with topical corticosteroids
نویسندگان
چکیده
So far in the literature there have been reported only 5 patients with a recognized and well-documented history of systemic lupus erythematosus (SLE) who developed SCLE after terbinafine introduction. Here we report two women suffering from SLE who developed SCLE after initiation of oral terbinafine for onychomycosis. Skin lesions in both of them were extensive, located on the trunk, and upper and lower extremities. No exacerbation of SLE symptoms was observed at that time. Despite severe skin lesions, patients revealed good response to topical corticosteroids within a few weeks. The systemic review of the literature and our experience on terbinafine-induced SCLE developing in patients with SLE allowed to create a description for this special subset: a) terbinafine-induced SCLE usually develop in 1-8 weeks after terbinafine introduction, b) skin lesions are usually severe, disseminated including lower extremities, c) patients present Ro/SS-A La/SS-B antibodies, but anti-histone antibodies are rarely observed, d) exacerbation of SLE symptoms is rather not observed, e) eruptions clear within 2-8 weeks, f) withdrawal of terbinafine and topical corticosteroids should be considered as a first-line therapy in these cases, g) terbinafine should be carefully used in patients suffering from SLE.
منابع مشابه
Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases.
BACKGROUND Subacute cutaneous lupus erythematosus is a nonscarring, non-atrophy-producing photosensitive cutaneous disorder. Half of the patients have 4 or more of the criteria for classification as systemic lupus erythematosus. In some patients, drugs induce or exacerbate the cutaneous disease. OBSERVATION We describe 5 patients who had either an exacerbation or a new onset of subacute cutan...
متن کاملSubacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy.
BACKGROUND Subacute cutaneous lupus erythematosus (SCLE), characterized by nonscarring, photodistributed, annular or papulosquamous plaques, is occasionally induced by medication. It has been strongly associated with antihypertensive medications and terbinafine hydrochloride. OBSERVATION We describe 3 women with breast cancer who developed SCLE-like eruptions after being administered doxorubi...
متن کاملTopical drug-induced subacute cutaneous lupus erythematosus isolated to the hands
Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histolo...
متن کاملHerpes zoster infection after topical steroid use in the setting of tumid lupus erythematosus
CLE: cutaneous lupus erythematosus HZ: herpes zoster SLE: systemic lupus erythematosus TLE: tumid lupus erythematosus VZV: varicella zoster virus INTRODUCTION Topical corticosteroids are commonly used in the treatment of a wide range of skin manifestations of systemic lupus erythematosus (SLE). Patients with SLE are also known to have an increased risk of herpes zoster (HZ). Here we present a r...
متن کاملCutaneous manifestations of systemic Lupus Erythematosus: A study from Ahwaz
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease in which cutaneous lesions occur in 72%-85% of patients. Objective: This study was conducted to determine the pattern and incidence of skin lesions in SLE patients in Ahwaz. Patients and Methods: Thirty patients with SLE fulfilling the clinical and laboratory criteria of the American Rheumatism Association who were admitted...
متن کامل